Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.43 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11902048 | 0.89 | KMT2A (0.45) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL3173765 | 0.86 | KMT2A (0.44) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL341372 | 0.85 | KMT2A (0.43) | KMT2AFABP5FABP7EPHX2OPRD1 | |
| SCHEMBL6651104 | 0.83 | KMT2A (0.41) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL2943202 | 0.82 | KMT2A (0.41) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL377928 | 0.81 | KMT2A (0.44) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL15297397 | 0.80 | USP30 (0.41) | KMT2AFABP5FABP7 | |
| SCHEMBL1869833 | 0.79 | FABP5 (0.50) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL3580338 | 0.78 | GPR119 (0.44) | KMT2A | |
| SCHEMBL2355443 | 0.78 | KMT2A (0.49) | KMT2AFABP5FABP7EPHX2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260036595-A1 | STRUCTURE-BASED PEPTIDES FOR DETECTION OF TRANSTHYRETIN AMYLOID FIBRILS AND AGGREGATES IN PREECLAMPSIA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250362310-A1 | STRUCTURE-BASED PROBE FOR DETECTION OF TRANSTHYRETIN AMYLOID FIBRILS AND AGGREGATES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-27 | — | — | US | disclosed |
| US-20040014676-A1 | SRC kinase inhibitors useful for treating osteoporosis | ARIAD PHARMACEUTICALS INC. | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014676-A1 | SRC kinase inhibitors useful for treating osteoporosis | SRC, CTTN, YES1 | KMT2A 1865/4885FABP5 2465/4885FABP7 4354/4885 |
| US-20260036595-A1 | STRUCTURE-BASED PEPTIDES FOR DETECTION OF TRANSTHYRETIN AMYLOID FIBRILS AND AGGREGATES IN PREECLAMPSIA | TTR, APP, SERPINA3 | KMT2A 4282/4885FABP5 115/4885FABP7 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.